The class of poly (ADP-ribose) polymerase inhibitors, once celebrated as a breakthrough in ovarian and breast cancer, has endured a reputation decline following safety concerns and regulatory rollbacks. But recent data suggest that prostate cancer, specifically metastatic castration-resistant prostate cancer with BRCA mutations, may offer PARP inhibitors a new lease on life.

The December 2025 FDA approval of Tolmar Inc.’s Rubraca (rucaparib) for pre-chemotherapy use in BRCA-positive prostate cancer patients marked a clinical and regulatory milestone. This label expansion, supported by the TRITON3 Phase 3 trial, showed Rubraca outperforming docetaxel in a direct comparison. This is something no other PARP inhibitor has achieved in a head-to-head study in urologic oncology.

With multiple agents now competing in the space, including AstraZeneca’s Lynparza (olaparib), GlaxoSmithKline’s Zejula (niraparib), and Pfizer’s Talzenna (talazoparib), analysts are asking whether prostate cancer is emerging as the most defensible and clinically compelling indication for the PARP inhibitor class. For a drug category still shadowed by regulatory pullbacks in ovarian cancer, this resurgence could represent a class-wide pivot.

What prostate cancer offers that ovarian cancer could not

The rise and fall of PARP inhibitors in ovarian cancer has been sharp. Initial enthusiasm gave way to concern when confirmatory studies failed to demonstrate overall survival benefit in broader maintenance populations. This led to multiple label withdrawals, including for Zejula and Lynparza in later-line settings, and a rethinking of risk-benefit thresholds for PARP maintenance therapy.

In contrast, prostate cancer may offer a cleaner clinical and regulatory trajectory. The biology of BRCA-mutated metastatic castration-resistant prostate cancer is distinct, with more aggressive progression and earlier treatment resistance. In this setting, PARP inhibitors have shown not just progression-free benefit but also strong biomarker-enriched efficacy.

Rubraca’s TRITON3 trial, which demonstrated statistically significant superiority over docetaxel in radiographic progression-free survival, was a high-water mark for the class. Unlike in ovarian cancer, where many approvals relied on single-arm studies or less rigorous comparators, TRITON3’s design directly challenged an active standard of care, enhancing regulatory and clinical confidence.

How each PARP agent is positioned in the prostate cancer landscape

Rubraca (rucaparib) now leads the pack in prostate cancer after securing an earlier-line label based on head-to-head superiority. The drug is indicated for BRCA-mutated mCRPC patients who have received androgen receptor–directed therapy but not chemotherapy. Its differentiation lies in both trial design and timing, offering monotherapy efficacy prior to the toxicity burden of taxane-based regimens.

Lynparza (olaparib), co-developed by AstraZeneca and Merck, has been the class frontrunner in market penetration and combination strategies. It holds an FDA approval for use in mCRPC patients with homologous recombination repair mutations, including BRCA1 and BRCA2, following prior novel hormonal therapy. However, Lynparza’s data come from PROfound, a trial that compared it to physician’s choice of enzalutamide or abiraterone rather than chemotherapy. While the study met its endpoints, the absence of direct comparison to taxanes may now be a differentiator.

Zejula (niraparib), developed by GlaxoSmithKline, is still exploring prostate cancer indications, with earlier trials producing mixed signals. A previous collaboration with Janssen for combination regimens with androgen receptor inhibitors failed to deliver decisive superiority. While Zejula remains active in other DDR-associated cancers, its prostate positioning is unclear following the ovarian label withdrawals.

Talzenna (talazoparib), co-developed by Pfizer and Astellas, has pursued a combination approach through the TALAPRO series. TALAPRO-2 evaluated talazoparib with enzalutamide in first-line mCRPC, reporting improved radiographic progression-free survival. However, toxicity concerns, particularly hematologic adverse events, have tempered enthusiasm. Unlike Rubraca, Talzenna is not yet approved as monotherapy in prostate cancer.

Collectively, this landscape highlights a trend. While several PARP agents have entered the mCRPC arena, only Rubraca has carved out a chemotherapy-displacing role. The rest rely on combination regimens or more restrictive labels that limit early adoption.

Why regulators may now favor mutation-first prostate cancer trials over maintenance-only ovarian models

One of the reasons PARP inhibitors fell out of favor in ovarian cancer was the expansion of use beyond biomarker-enriched populations. Many of the original maintenance indications did not require BRCA or homologous recombination deficiency, leading to concerns about benefit dilution, overtreatment, and adverse event burden.

The prostate cancer setting is different. Trials like TRITON3 and PROfound used strict molecular enrollment criteria, targeting BRCA1, BRCA2, and ATM mutations with companion diagnostics. This alignment between genetic selection, trial design, and drug efficacy has produced cleaner datasets and stronger regulatory narratives.

Moreover, prostate cancer has seen relatively little biomarker stratification compared to lung or breast cancer. This opens an opportunity for PARP inhibitors to define a new standard in an under-segmented disease space. Industry observers believe the FDA may now prefer these mutation-first strategies over unselected maintenance use, especially following the ovarian reversals.

What still threatens the long-term positioning of PARP inhibitors in urologic oncology

Despite Rubraca’s recent success, the class still faces meaningful challenges. Chief among them is sequencing uncertainty. With PARP inhibitors now being used earlier in the treatment algorithm, oncologists have limited data on the efficacy of subsequent lines of therapy. Whether taxanes, androgen receptor inhibitors, or other targeted agents retain efficacy after PARP progression remains poorly defined.

Toxicity remains another concern. Hematologic adverse events, especially anemia and thrombocytopenia, are common across the class. In combination settings, such as those pursued by Talzenna and Lynparza, these risks are amplified. Clinicians may need better predictive tools to identify patients who can tolerate extended dual therapy regimens.

Access and reimbursement could also limit uptake. Companion diagnostic alignment has helped secure coverage in BRCA-positive patients, but broader homologous recombination deficiency testing remains inconsistent. Payer hesitancy, particularly in community settings, could stifle real-world adoption despite regulatory approvals.

Additionally, competition from emerging modalities including radioligand therapies and next-generation androgen receptor degraders may crowd the treatment landscape, especially if they offer biomarker-agnostic efficacy or improved safety.

Why prostate cancer may become the anchor indication for class survival

Given these dynamics, prostate cancer is increasingly viewed as the class’s most defensible market. Unlike ovarian cancer, where the unmet need has narrowed and risk tolerance has declined, mCRPC represents a biologically aggressive, genomically identifiable niche where targeted therapy is underutilized.

Regulators appear to support this evolution. The FDA’s willingness to grant earlier-line approval to Rubraca based on BRCA-enriched, comparator-controlled data signals a preference for molecular precision over broad empiricism.

From a commercial standpoint, mCRPC patients with BRCA mutations often experience rapid progression through androgen-targeted agents, making them ideal candidates for early-line intervention. This allows PARP inhibitors to occupy a high-value niche where both efficacy and urgency are clinically aligned.

As other agents in the class pursue post-marketing studies or new indications, prostate cancer could become the reference point for future regulatory submissions. And for a therapeutic class still working to rebuild its reputation, such an anchor is essential.

What to watch next: Class divergence or consolidation?

The coming year may determine whether PARP inhibitors continue to evolve as a competitive class or whether one or two agents consolidate the space. Rubraca’s clinical positioning, if supported by real-world data and reimbursement momentum, could accelerate its lead. Lynparza, while still widely used, may need new trial wins to defend its mCRPC franchise.

Zejula and Talzenna face tougher paths. Without decisive monotherapy data or superior tolerability, they risk becoming secondary options unless combination regimens prove durable and tolerable. Strategic partnerships, licensing deals, or even divestitures may follow if commercial traction does not materialize.

Clinicians, meanwhile, will be watching for updates to treatment guidelines, sequencing protocols, and diagnostic mandates. If PARP inhibitors become firmly embedded in the early-line management of BRCA-mutated prostate cancer, their standing across oncology may recover more broadly.

  AstraZeneca, DDR biomarkers, Lynparza, mCRPC, oncology trials, PARP inhibitors, prostate cancer, Rubraca, Talzenna, Tolmar Inc., TRITON3, Zejula